A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL)
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs ME 401 (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions
- Sponsors MEI Pharma
- 31 May 2017 According to an MEI Pharma media release, an independent Safety Review Committee has completed its pre-specified review of the first cohort of six evaluable patients and declared a minimum biologically effective dose (mBED) for ME-401 at the starting dose of 60 mg and recommended escalation to a 120 mg dose cohort. Full data will be submitted for presentation at an upcoming scientific meeting.
- 04 May 2017 According to a MEI Pharma media release, interim safety and efficacy data from the first cohort of the study are expected in June.
- 08 Nov 2016 Status changed from not yet recruiting to recruiting.